A Single-Center, Cross-over, Pilot Study Evaluating Acuvue® Oasys® Lenses (Senofilcon A), 30-Day Bausch + Lomb PureVision (Balafilcon A), and Clariti® 1-Day (Somofilcon A) Lenses, for Their Impact on Ocular Discomfort Induced by Exposure to the Turbo Controlled Adverse Environment™
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- Locations
- 1
- Primary Endpoint
- Contact lens wear comfort, as assessed by subject reported symptoms in diaries.
Study Overview
Brief Summary
The purpose of this study is to compare the comfort of three commercially available contact lenses.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Be at least 18 years old
- •Have provided written informed consent
- •Have discomfort when wearing contact lenses
Exclusion Criteria
- •Have an active ocular infection or significant slit lamp findings
- •Participated in any other studies in the past 30 days
Arms & Interventions
Clariti® 1-Day (Somofilcon A)
Clariti® 1-Day (Somofilcon A) contact lenses
Intervention: 30-Day Bausch + Lomb PureVision (balafilcon A) (Device)
Acuvue®Oasys® Lenses(senofilcon A)
Acuvue® Oasys® Lenses (senofilcon A) contact lenses
Intervention: Acuvue® Oasys® Lenses (senofilcon A) (Device)
Acuvue®Oasys® Lenses(senofilcon A)
Acuvue® Oasys® Lenses (senofilcon A) contact lenses
Intervention: 30-Day Bausch + Lomb PureVision (balafilcon A) (Device)
Acuvue®Oasys® Lenses(senofilcon A)
Acuvue® Oasys® Lenses (senofilcon A) contact lenses
Intervention: Clariti® 1-Day (Somofilcon A) (Device)
Bausch + Lomb PureVision (balafilcon A)
30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
Intervention: Acuvue® Oasys® Lenses (senofilcon A) (Device)
Bausch + Lomb PureVision (balafilcon A)
30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
Intervention: 30-Day Bausch + Lomb PureVision (balafilcon A) (Device)
Bausch + Lomb PureVision (balafilcon A)
30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
Intervention: Clariti® 1-Day (Somofilcon A) (Device)
Clariti® 1-Day (Somofilcon A)
Clariti® 1-Day (Somofilcon A) contact lenses
Intervention: Acuvue® Oasys® Lenses (senofilcon A) (Device)
Clariti® 1-Day (Somofilcon A)
Clariti® 1-Day (Somofilcon A) contact lenses
Intervention: Clariti® 1-Day (Somofilcon A) (Device)
Outcomes
Primary Outcomes
Contact lens wear comfort, as assessed by subject reported symptoms in diaries.
Time Frame: 1 week
Secondary Outcomes
No secondary outcomes reported